Trials / Completed
CompletedNCT02550418
Budesonide 9 mg Capsules in Active UC
Open-label, Multi-centre, Proof of Concept Phase IIa Clinical Trial on the Efficacy and Tolerability of an 8 Week Oral Treatment With Once Daily 9 mg Budesonide in Patients With Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2015-09-15
- Last updated
- 2017-07-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02550418. Inclusion in this directory is not an endorsement.